429 related articles for article (PubMed ID: 27543429)
1. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
Dai B; Hackney JA; Ichikawa R; Nguyen A; Elstrott J; Orozco LD; Sun KH; Modrusan Z; Gogineni A; Scherl A; Gubatan J; Habtezion A; Deswal M; Somsouk M; Faubion WA; Chai A; Sharafali Z; Hassanali A; Oh YS; Tole S; McBride J; Keir ME; Yi T
Cell Rep Med; 2021 Aug; 2(8):100381. PubMed ID: 34467254
[TBL] [Abstract][Full Text] [Related]
3. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.
Sommer K; Heidbreder K; Kreiss L; Dedden M; Paap EM; Wiendl M; Becker E; Atreya R; Müller TM; Atreya I; Waldner M; Schürmann S; Friedrich O; Neurath MF; Zundler S
Clin Transl Med; 2023 Apr; 13(4):e1233. PubMed ID: 37029786
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.
Fischer A; Zundler S; Atreya R; Rath T; Voskens C; Hirschmann S; López-Posadas R; Watson A; Becker C; Schuler G; Neufert C; Atreya I; Neurath MF
Gut; 2016 Oct; 65(10):1642-64. PubMed ID: 26209553
[TBL] [Abstract][Full Text] [Related]
5. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
6. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
7. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
8. Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease.
Keir ME; Fuh F; Ichikawa R; Acres M; Hackney JA; Hulme G; Carey CD; Palmer J; Jones CJ; Long AK; Jiang J; Klabunde S; Mansfield JC; Looney CM; Faubion WA; Filby A; Kirby JA; McBride J; Lamb CA
J Immunol; 2021 Nov; 207(9):2245-2254. PubMed ID: 34561227
[TBL] [Abstract][Full Text] [Related]
9. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
11. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
12. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
Zundler S; Neurath MF
Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
[TBL] [Abstract][Full Text] [Related]
13. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
14. A mutation that blocks integrin α
Zhang H; Zheng Y; Pan Y; Lin C; Wang S; Yan Z; Lu L; Ge G; Li J; Zeng YA; Chen J
BMC Biol; 2020 Jun; 18(1):64. PubMed ID: 32522281
[TBL] [Abstract][Full Text] [Related]
15. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease.
Apostolaki M; Manoloukos M; Roulis M; Wurbel MA; Müller W; Papadakis KA; Kontoyiannis DL; Malissen B; Kollias G
Gastroenterology; 2008 Jun; 134(7):2025-35. PubMed ID: 18439426
[TBL] [Abstract][Full Text] [Related]
16. αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
Lamb CA; Mansfield JC; Tew GW; Gibbons D; Long AK; Irving P; Diehl L; Eastham-Anderson J; Price MB; O'Boyle G; Jones DEJ; O'Byrne S; Hayday A; Keir ME; Egen JG; Kirby JA
J Crohns Colitis; 2017 May; 11(5):610-620. PubMed ID: 28453768
[TBL] [Abstract][Full Text] [Related]
17. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
18. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
[TBL] [Abstract][Full Text] [Related]
19. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin.
Van Damme N; Elewaut D; Baeten D; Demetter P; Cuvelier C; Verbruggen G; Mielants H; Veys EM; De Vos M; De Keyser F
Clin Exp Rheumatol; 2001; 19(6):681-7. PubMed ID: 11791640
[TBL] [Abstract][Full Text] [Related]
20. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
